Cargando…
Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19
Vaccines against SARS-CoV-2 have been pivotal in overcoming the COVID-19 pandemic yet understanding the subsequent outcomes and immunological effects remain crucial, especially for at-risk groups e.g., people living with human immunodeficiency virus (HIV) (PLWH). In this study we report the longitud...
Autores principales: | Smith, Muneerah, Kwatra, Gaurav, Izu, Alane, Nel, Andrew, Cutland, Clare, Ahmed, Khatja, Baillie, Vicky, Barnabas, Shaun, Bhorat, Qasim, Briner, Carmen, Lazarus, Erica, Dheda, Keertan, Fairlie, Lee, Koen, Anthonet, Madhi, Shabir, Blackburn, Jonathan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965153/ https://www.ncbi.nlm.nih.gov/pubmed/36851662 http://dx.doi.org/10.3390/v15020448 |
Ejemplares similares
-
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
por: Kaplonek, Paulina, et al.
Publicado: (2023) -
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005)
por: Koen, Anthonet L., et al.
Publicado: (2023) -
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
por: Madhi, Shabir A, et al.
Publicado: (2021) -
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
por: Madhi, Shabir A., et al.
Publicado: (2021) -
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial
por: Madhi, Shabir A, et al.
Publicado: (2023)